Revelation Biosciences, Inc.
REVBNASDAQHealthcare● Active
$1.03
+$0.02(+1.49%)
Market Cap$4006130
P/E Ratio—
52W High$12.88
52W Low$0.875
Revelation Biosciences, Inc. (REVB) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · REVB · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.01B) | ($0.02B) | ($0.00B) | ($0.01B) | ($0.01B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.00B) | ($0.00B) | $0.00B | ($0.00B) | $0.00B |
| Net Cash from Operations | ($0.01B) | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | ($0.00B) | $0.00B | $0.00B | ($0.00B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | $0.00B | ($0.00B) | $0.00B | $0.00B | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Net Cash from Financing | $0.01B | $0.01B | $0.01B | $0.02B | $0.01B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.01B) | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Revelation Biosciences, Inc. data
About Revelation Biosciences, Inc. (REVB) Cash Flow Statement
Revelation Biosciences, Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
REVB · 4 questionsRevelation Biosciences, Inc. generated free cash flow of ($0.01B) for 2025, up 54.9% year-over-year.
REVB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10